China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National Science Center’s Institute of Health and Medicine and Hefei Afana Biotechnology Co., Ltd to establish a joint laboratory. The new lab will concentrate on advancing biotechnology innovation and translational medicine.
Leveraging Core Competencies for Nucleic Acid Drug Development
The collaboration will capitalize on CR Bio’s established strengths within the industry, the Institute’s prowess in basic research and science translation, and Afana Bio’s expertise in nucleic acid drug development. Together, they aim to make significant strides in the nucleic acid drug sector, although no financial details of the partnership have been disclosed.
Enhancing Translational Medicine and Biotechnology
This joint laboratory represents a significant step forward in the field of biotechnology, combining the resources and expertise of three key players to drive innovation and translational medicine. The partnership is expected to yield valuable outcomes that could reshape the landscape of nucleic acid drug development and treatment.-Fineline Info & Tech
